Takeda Pharmaceutical Co., Ltd. (4502) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Astellas Pharma, Inc.

Kyowa Kirin Co., Ltd.

Shionogi & Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Daiichi Sankyo Co., Ltd.

Eisai Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is Takeda Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 5.23%

The company has been able to generate a Return on Capital Employed (avg) of 5.23% signifying low profitability per unit of total capital (equity and debt)

The company is Net-Debt Free

The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 4.58% signifying low profitability per unit of shareholders funds

High Debt company with Weak Long Term Fundamental Strength

Flat results in Jun 26

NET PROFIT(HY) At JPY -143,372 MM has Grown at -250.62%
ROCE(HY) Lowest at -2.27%
INVENTORY TURNOVER RATIO(HY) Lowest at 1.56 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 30.97%, its profits have fallen by -22.2%
At the current price, the company has a high dividend yield of 0

Underperformed the market in the last 1 year

The stock has generated a return of 30.97% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 59.79%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Takeda Pharmaceutical Co., Ltd. for you?

Low Risk, High Return

Absolute

Risk Adjusted

Volatility

Takeda Pharmaceutical Co., Ltd.

30.88%

660.73

22.51%

Japan Nikkei 225

60.14%

2.04

29.37%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.89%

EBIT Growth (5y)

2.47%

EBIT to Interest (avg)

2.45

Debt to EBITDA (avg)

3.21

Net Debt to Equity (avg)

0.60

Sales to Capital Employed (avg)

0.37

Tax Ratio

6.97%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.13%

ROCE (avg)

5.32%

ROE (avg)

4.58%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.05

EV to EBIT

23.25

EV to EBITDA

9.44

EV to Capital Employed

1.03

EV to Sales

2.73

PEG Ratio

Dividend Yield

ROCE (Latest)

4.43%

ROE (Latest)

2.45%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company

NET PROFIT(Q)

At JPY 113,196 MM has Grown at 1,218.34%

RAW MATERIAL COST(Y)

Fallen by -8.06% (YoY

NET SALES(Q)

Highest at JPY 1,219,900 MM

OPERATING PROFIT(Q)

Highest at JPY 411,430 MM

OPERATING PROFIT MARGIN(Q)

Highest at 33.73 %

PRE-TAX PROFIT(Q)

Highest at JPY 162,180 MM

-19What is not working for the Company

NET PROFIT(HY)

At JPY -143,372 MM has Grown at -250.62%

ROCE(HY)

Lowest at -2.27%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.56 times

INTEREST(Q)

At JPY 63,845 MM has Grown at 46.27%

Here's what is working for Takeda Pharmaceutical Co., Ltd.

Pre-Tax Profit

At JPY 162,180 MM has Grown at 2,394.24%

over average net sales of the previous four periods of JPY -7,069 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (JPY MM)

Net Profit

At JPY 113,196 MM has Grown at 1,218.34%

over average net sales of the previous four periods of JPY -10,121.75 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (JPY MM)

Net Sales

Highest at JPY 1,219,900 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Operating Profit

Highest at JPY 411,430 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JPY MM)

Operating Profit Margin

Highest at 33.73 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at JPY 162,180 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Raw Material Cost

Fallen by -8.06% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Takeda Pharmaceutical Co., Ltd.

Interest

At JPY 63,845 MM has Grown at 46.27%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Inventory Turnover Ratio

Lowest at 1.56 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio